The Anti-Müllerian hormone (AMH) is a member of the transforming growth factor ß family of growth and differentiation factors. In the ovaries, AMH has an inhibitory effect on primordial follicle recruitment as well as on the responsiveness of growing follicles to follicle-stimulating hormone (FSH).


Anti-Müllerian hormone (AMH) has been recently proposed as a marker for ovarian ageing and poor ovarian response to controlled ovarian hyperstimulation in assisted reproduction cycles (“in vitro fertilization”).


Serum anti-Müllerian hormone (AMH) levels provide a powerful means for predicting ovarian response, which is reflected not only by the size of the primordial follicle pool but also by the quality of the oocytes. Levels of AMH under 1,66 ng/ml or above 4,52 ng/ml indicates low quality oocytes. Levels of AMH between 1,66 and 4,52 ng/mg promise high quality oocytes but do not guarantee that pregnancy will occur.


Nobody knows the answer to the second question you ask, "Can the anti mullerian hormone result ever change, i.e get better?".Premature ovulation failure (POF) is generally treated with hormone replacement therapy (HRT). 8 % of patients treated via HRT report success in achieving pregnancy.